Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Thermal Ablation in HCC
NCT03864211Phase 2Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Xiangya Hospital, Central South University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03864211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864211.